Global Treating Chronic Myeloid Leukemia by Phase Supply, Demand and Key Producers, 2024-2030

Description

The treatment of chronic myeloid leukemia (CML) is structured around the disease's phases: chronic, accelerated, and blast. In the chronic phase, first-line therapy typically involves tyrosine kinase inhibitors (TKIs) such as imatinib, dasatinib, or nilotinib. If CML progresses to the accelerated phase, treatment may shift to a different TKI, combination therapies, or clinical trials to manage resistance. In the blast phase, characterized by acute leukemia-like features, more intensive treatments such as chemotherapy or stem cell transplantation are often required.

The global Treating Chronic Myeloid Leukemia by Phase market size is expected to reach $ million by 2030, rising at a market growth of %CAGR during the forecast period (2024-2030).

This report studies the global Treating Chronic Myeloid Leukemia by Phase demand, key companies, and key regions.

This report is a detailed and comprehensive analysis of the world market for Treating Chronic Myeloid Leukemia by Phase, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2023 as the base year. This report explores demand trends and competition, as well as details the characteristics of Treating Chronic Myeloid Leukemia by Phase that contribute to its increasing demand across many markets.

Highlights and key features of the study
Global Treating Chronic Myeloid Leukemia by Phase total market, 2019-2030, (USD Million)
Global Treating Chronic Myeloid Leukemia by Phase total market by region & country, CAGR, 2019-2030, (USD Million)
U.S. VS China: Treating Chronic Myeloid Leukemia by Phase total market, key domestic companies, and share, (USD Million)
Global Treating Chronic Myeloid Leukemia by Phase revenue by player, revenue and market share 2019-2024, (USD Million)
Global Treating Chronic Myeloid Leukemia by Phase total market by Type, CAGR, 2019-2030, (USD Million)
Global Treating Chronic Myeloid Leukemia by Phase total market by Application, CAGR, 2019-2030, (USD Million)
This report profiles major players in the global Treating Chronic Myeloid Leukemia by Phase market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Novartis, Bristol Myers Squibb, Pfizer, Hansoh Pharmaceutical, Takeda Pharmaceuticals, Sun Pharmaceuticals, Mylan, Dr. Reddy's Laboratories, Teva, Eugia Pharma, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the world Treating Chronic Myeloid Leukemia by Phase market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2019-2030 by year with 2023 as the base year, 2024 as the estimate year, and 2025-2030 as the forecast year.

Global Treating Chronic Myeloid Leukemia by Phase Market, By Region:
    United States
    China
    Europe
    Japan
    South Korea
    ASEAN
    India
    Rest of World

Global Treating Chronic Myeloid Leukemia by Phase Market, Segmentation by Type
    Chronic Phase
    Accelerated Phase
    Blast Phase

Global Treating Chronic Myeloid Leukemia by Phase Market, Segmentation by Application:
    Hospitals
    Clinics
    Others

Companies Profiled:
    Novartis
    Bristol Myers Squibb
    Pfizer
    Hansoh Pharmaceutical
    Takeda Pharmaceuticals
    Sun Pharmaceuticals
    Mylan
    Dr. Reddy's Laboratories
    Teva
    Eugia Pharma
    Hetero
    Sawai Pharmaceutical
    Lupin
    Apotex
    Chia Tai Tianqing Pharmaceutical
    Qilu Pharmaceutical
    CSPC Ouyi Pharmaceutical
    Suzhou Thery Pharmaceutical
    Lunan Pharmaceutical

Key Questions Answered
1. How big is the global Treating Chronic Myeloid Leukemia by Phase market?
2. What is the demand of the global Treating Chronic Myeloid Leukemia by Phase market?
3. What is the year over year growth of the global Treating Chronic Myeloid Leukemia by Phase market?
4. What is the total value of the global Treating Chronic Myeloid Leukemia by Phase market?
5. Who are the Major Players in the global Treating Chronic Myeloid Leukemia by Phase market?
6. What are the growth factors driving the market demand?

Table of Contents

1 Supply Summary
    1.1 Treating Chronic Myeloid Leukemia by Phase Introduction
    1.2 World Treating Chronic Myeloid Leukemia by Phase Market Size & Forecast (2019 & 2023 & 2030)
    1.3 World Treating Chronic Myeloid Leukemia by Phase Total Market by Region (by Headquarter Location)
        1.3.1 World Treating Chronic Myeloid Leukemia by Phase Market Size by Region (2019-2030), (by Headquarter Location)
        1.3.2 United States Based Company Treating Chronic Myeloid Leukemia by Phase Revenue (2019-2030)
        1.3.3 China Based Company Treating Chronic Myeloid Leukemia by Phase Revenue (2019-2030)
        1.3.4 Europe Based Company Treating Chronic Myeloid Leukemia by Phase Revenue (2019-2030)
        1.3.5 Japan Based Company Treating Chronic Myeloid Leukemia by Phase Revenue (2019-2030)
        1.3.6 South Korea Based Company Treating Chronic Myeloid Leukemia by Phase Revenue (2019-2030)
        1.3.7 ASEAN Based Company Treating Chronic Myeloid Leukemia by Phase Revenue (2019-2030)
        1.3.8 India Based Company Treating Chronic Myeloid Leukemia by Phase Revenue (2019-2030)
    1.4 Market Drivers, Restraints and Trends
        1.4.1 Treating Chronic Myeloid Leukemia by Phase Market Drivers
        1.4.2 Factors Affecting Demand
        1.4.3 Major Market Trends

2 Demand Summary
    2.1 World Treating Chronic Myeloid Leukemia by Phase Consumption Value (2019-2030)
    2.2 World Treating Chronic Myeloid Leukemia by Phase Consumption Value by Region
        2.2.1 World Treating Chronic Myeloid Leukemia by Phase Consumption Value by Region (2019-2024)
        2.2.2 World Treating Chronic Myeloid Leukemia by Phase Consumption Value Forecast by Region (2025-2030)
    2.3 United States Treating Chronic Myeloid Leukemia by Phase Consumption Value (2019-2030)
    2.4 China Treating Chronic Myeloid Leukemia by Phase Consumption Value (2019-2030)
    2.5 Europe Treating Chronic Myeloid Leukemia by Phase Consumption Value (2019-2030)
    2.6 Japan Treating Chronic Myeloid Leukemia by Phase Consumption Value (2019-2030)
    2.7 South Korea Treating Chronic Myeloid Leukemia by Phase Consumption Value (2019-2030)
    2.8 ASEAN Treating Chronic Myeloid Leukemia by Phase Consumption Value (2019-2030)
    2.9 India Treating Chronic Myeloid Leukemia by Phase Consumption Value (2019-2030)

3 World Treating Chronic Myeloid Leukemia by Phase Companies Competitive Analysis
    3.1 World Treating Chronic Myeloid Leukemia by Phase Revenue by Player (2019-2024)
    3.2 Industry Rank and Concentration Rate (CR)
        3.2.1 Global Treating Chronic Myeloid Leukemia by Phase Industry Rank of Major Players
        3.2.2 Global Concentration Ratios (CR4) for Treating Chronic Myeloid Leukemia by Phase in 2023
        3.2.3 Global Concentration Ratios (CR8) for Treating Chronic Myeloid Leukemia by Phase in 2023
    3.3 Treating Chronic Myeloid Leukemia by Phase Company Evaluation Quadrant
    3.4 Treating Chronic Myeloid Leukemia by Phase Market: Overall Company Footprint Analysis
        3.4.1 Treating Chronic Myeloid Leukemia by Phase Market: Region Footprint
        3.4.2 Treating Chronic Myeloid Leukemia by Phase Market: Company Product Type Footprint
        3.4.3 Treating Chronic Myeloid Leukemia by Phase Market: Company Product Application Footprint
    3.5 Competitive Environment
        3.5.1 Historical Structure of the Industry
        3.5.2 Barriers of Market Entry
        3.5.3 Factors of Competition
    3.6 Mergers & Acquisitions Activity

4 United States VS China VS Rest of World (by Headquarter Location)
    4.1 United States VS China: Treating Chronic Myeloid Leukemia by Phase Revenue Comparison (by Headquarter Location)
        4.1.1 United States VS China: Treating Chronic Myeloid Leukemia by Phase Revenue Comparison (2019 & 2023 & 2030) (by Headquarter Location)
        4.1.2 United States VS China: Treating Chronic Myeloid Leukemia by Phase Revenue Market Share Comparison (2019 & 2023 & 2030)
    4.2 United States Based Companies VS China Based Companies: Treating Chronic Myeloid Leukemia by Phase Consumption Value Comparison
        4.2.1 United States VS China: Treating Chronic Myeloid Leukemia by Phase Consumption Value Comparison (2019 & 2023 & 2030)
        4.2.2 United States VS China: Treating Chronic Myeloid Leukemia by Phase Consumption Value Market Share Comparison (2019 & 2023 & 2030)
    4.3 United States Based Treating Chronic Myeloid Leukemia by Phase Companies and Market Share, 2019-2024
        4.3.1 United States Based Treating Chronic Myeloid Leukemia by Phase Companies, Headquarters (States, Country)
        4.3.2 United States Based Companies Treating Chronic Myeloid Leukemia by Phase Revenue, (2019-2024)
    4.4 China Based Companies Treating Chronic Myeloid Leukemia by Phase Revenue and Market Share, 2019-2024
        4.4.1 China Based Treating Chronic Myeloid Leukemia by Phase Companies, Company Headquarters (Province, Country)
        4.4.2 China Based Companies Treating Chronic Myeloid Leukemia by Phase Revenue, (2019-2024)
    4.5 Rest of World Based Treating Chronic Myeloid Leukemia by Phase Companies and Market Share, 2019-2024
        4.5.1 Rest of World Based Treating Chronic Myeloid Leukemia by Phase Companies, Headquarters (Province, Country)
        4.5.2 Rest of World Based Companies Treating Chronic Myeloid Leukemia by Phase Revenue (2019-2024)

5 Market Analysis by Type
    5.1 World Treating Chronic Myeloid Leukemia by Phase Market Size Overview by Type: 2019 VS 2023 VS 2030
    5.2 Segment Introduction by Type
        5.2.1 Chronic Phase
        5.2.2 Accelerated Phase
        5.2.3 Blast Phase
    5.3 Market Segment by Type
        5.3.1 World Treating Chronic Myeloid Leukemia by Phase Market Size by Type (2019-2024)
        5.3.2 World Treating Chronic Myeloid Leukemia by Phase Market Size by Type (2025-2030)
        5.3.3 World Treating Chronic Myeloid Leukemia by Phase Market Size Market Share by Type (2025-2030)

6 Market Analysis by Application
    6.1 World Treating Chronic Myeloid Leukemia by Phase Market Size Overview by Application: 2019 VS 2023 VS 2030
    6.2 Segment Introduction by Application
        6.2.1 Hospitals
        6.2.2 Clinics
        6.2.3 Others
    6.3 Market Segment by Application
        6.3.1 World Treating Chronic Myeloid Leukemia by Phase Market Size by Application (2019-2024)
        6.3.2 World Treating Chronic Myeloid Leukemia by Phase Market Size by Application (2025-2030)
        6.3.3 World Treating Chronic Myeloid Leukemia by Phase Market Size Market Share by Application (2019-2030)

7 Company Profiles
    7.1 Novartis
        7.1.1 Novartis Details
        7.1.2 Novartis Major Business
        7.1.3 Novartis Treating Chronic Myeloid Leukemia by Phase Product and Services
        7.1.4 Novartis Treating Chronic Myeloid Leukemia by Phase Revenue, Gross Margin and Market Share (2019-2024)
        7.1.5 Novartis Recent Developments/Updates
        7.1.6 Novartis Competitive Strengths & Weaknesses
    7.2 Bristol Myers Squibb
        7.2.1 Bristol Myers Squibb Details
        7.2.2 Bristol Myers Squibb Major Business
        7.2.3 Bristol Myers Squibb Treating Chronic Myeloid Leukemia by Phase Product and Services
        7.2.4 Bristol Myers Squibb Treating Chronic Myeloid Leukemia by Phase Revenue, Gross Margin and Market Share (2019-2024)
        7.2.5 Bristol Myers Squibb Recent Developments/Updates
        7.2.6 Bristol Myers Squibb Competitive Strengths & Weaknesses
    7.3 Pfizer
        7.3.1 Pfizer Details
        7.3.2 Pfizer Major Business
        7.3.3 Pfizer Treating Chronic Myeloid Leukemia by Phase Product and Services
        7.3.4 Pfizer Treating Chronic Myeloid Leukemia by Phase Revenue, Gross Margin and Market Share (2019-2024)
        7.3.5 Pfizer Recent Developments/Updates
        7.3.6 Pfizer Competitive Strengths & Weaknesses
    7.4 Hansoh Pharmaceutical
        7.4.1 Hansoh Pharmaceutical Details
        7.4.2 Hansoh Pharmaceutical Major Business
        7.4.3 Hansoh Pharmaceutical Treating Chronic Myeloid Leukemia by Phase Product and Services
        7.4.4 Hansoh Pharmaceutical Treating Chronic Myeloid Leukemia by Phase Revenue, Gross Margin and Market Share (2019-2024)
        7.4.5 Hansoh Pharmaceutical Recent Developments/Updates
        7.4.6 Hansoh Pharmaceutical Competitive Strengths & Weaknesses
    7.5 Takeda Pharmaceuticals
        7.5.1 Takeda Pharmaceuticals Details
        7.5.2 Takeda Pharmaceuticals Major Business
        7.5.3 Takeda Pharmaceuticals Treating Chronic Myeloid Leukemia by Phase Product and Services
        7.5.4 Takeda Pharmaceuticals Treating Chronic Myeloid Leukemia by Phase Revenue, Gross Margin and Market Share (2019-2024)
        7.5.5 Takeda Pharmaceuticals Recent Developments/Updates
        7.5.6 Takeda Pharmaceuticals Competitive Strengths & Weaknesses
    7.6 Sun Pharmaceuticals
        7.6.1 Sun Pharmaceuticals Details
        7.6.2 Sun Pharmaceuticals Major Business
        7.6.3 Sun Pharmaceuticals Treating Chronic Myeloid Leukemia by Phase Product and Services
        7.6.4 Sun Pharmaceuticals Treating Chronic Myeloid Leukemia by Phase Revenue, Gross Margin and Market Share (2019-2024)
        7.6.5 Sun Pharmaceuticals Recent Developments/Updates
        7.6.6 Sun Pharmaceuticals Competitive Strengths & Weaknesses
    7.7 Mylan
        7.7.1 Mylan Details
        7.7.2 Mylan Major Business
        7.7.3 Mylan Treating Chronic Myeloid Leukemia by Phase Product and Services
        7.7.4 Mylan Treating Chronic Myeloid Leukemia by Phase Revenue, Gross Margin and Market Share (2019-2024)
        7.7.5 Mylan Recent Developments/Updates
        7.7.6 Mylan Competitive Strengths & Weaknesses
    7.8 Dr. Reddy's Laboratories
        7.8.1 Dr. Reddy's Laboratories Details
        7.8.2 Dr. Reddy's Laboratories Major Business
        7.8.3 Dr. Reddy's Laboratories Treating Chronic Myeloid Leukemia by Phase Product and Services
        7.8.4 Dr. Reddy's Laboratories Treating Chronic Myeloid Leukemia by Phase Revenue, Gross Margin and Market Share (2019-2024)
        7.8.5 Dr. Reddy's Laboratories Recent Developments/Updates
        7.8.6 Dr. Reddy's Laboratories Competitive Strengths & Weaknesses
    7.9 Teva
        7.9.1 Teva Details
        7.9.2 Teva Major Business
        7.9.3 Teva Treating Chronic Myeloid Leukemia by Phase Product and Services
        7.9.4 Teva Treating Chronic Myeloid Leukemia by Phase Revenue, Gross Margin and Market Share (2019-2024)
        7.9.5 Teva Recent Developments/Updates
        7.9.6 Teva Competitive Strengths & Weaknesses
    7.10 Eugia Pharma
        7.10.1 Eugia Pharma Details
        7.10.2 Eugia Pharma Major Business
        7.10.3 Eugia Pharma Treating Chronic Myeloid Leukemia by Phase Product and Services
        7.10.4 Eugia Pharma Treating Chronic Myeloid Leukemia by Phase Revenue, Gross Margin and Market Share (2019-2024)
        7.10.5 Eugia Pharma Recent Developments/Updates
        7.10.6 Eugia Pharma Competitive Strengths & Weaknesses
    7.11 Hetero
        7.11.1 Hetero Details
        7.11.2 Hetero Major Business
        7.11.3 Hetero Treating Chronic Myeloid Leukemia by Phase Product and Services
        7.11.4 Hetero Treating Chronic Myeloid Leukemia by Phase Revenue, Gross Margin and Market Share (2019-2024)
        7.11.5 Hetero Recent Developments/Updates
        7.11.6 Hetero Competitive Strengths & Weaknesses
    7.12 Sawai Pharmaceutical
        7.12.1 Sawai Pharmaceutical Details
        7.12.2 Sawai Pharmaceutical Major Business
        7.12.3 Sawai Pharmaceutical Treating Chronic Myeloid Leukemia by Phase Product and Services
        7.12.4 Sawai Pharmaceutical Treating Chronic Myeloid Leukemia by Phase Revenue, Gross Margin and Market Share (2019-2024)
        7.12.5 Sawai Pharmaceutical Recent Developments/Updates
        7.12.6 Sawai Pharmaceutical Competitive Strengths & Weaknesses
    7.13 Lupin
        7.13.1 Lupin Details
        7.13.2 Lupin Major Business
        7.13.3 Lupin Treating Chronic Myeloid Leukemia by Phase Product and Services
        7.13.4 Lupin Treating Chronic Myeloid Leukemia by Phase Revenue, Gross Margin and Market Share (2019-2024)
        7.13.5 Lupin Recent Developments/Updates
        7.13.6 Lupin Competitive Strengths & Weaknesses
    7.14 Apotex
        7.14.1 Apotex Details
        7.14.2 Apotex Major Business
        7.14.3 Apotex Treating Chronic Myeloid Leukemia by Phase Product and Services
        7.14.4 Apotex Treating Chronic Myeloid Leukemia by Phase Revenue, Gross Margin and Market Share (2019-2024)
        7.14.5 Apotex Recent Developments/Updates
        7.14.6 Apotex Competitive Strengths & Weaknesses
    7.15 Chia Tai Tianqing Pharmaceutical
        7.15.1 Chia Tai Tianqing Pharmaceutical Details
        7.15.2 Chia Tai Tianqing Pharmaceutical Major Business
        7.15.3 Chia Tai Tianqing Pharmaceutical Treating Chronic Myeloid Leukemia by Phase Product and Services
        7.15.4 Chia Tai Tianqing Pharmaceutical Treating Chronic Myeloid Leukemia by Phase Revenue, Gross Margin and Market Share (2019-2024)
        7.15.5 Chia Tai Tianqing Pharmaceutical Recent Developments/Updates
        7.15.6 Chia Tai Tianqing Pharmaceutical Competitive Strengths & Weaknesses
    7.16 Qilu Pharmaceutical
        7.16.1 Qilu Pharmaceutical Details
        7.16.2 Qilu Pharmaceutical Major Business
        7.16.3 Qilu Pharmaceutical Treating Chronic Myeloid Leukemia by Phase Product and Services
        7.16.4 Qilu Pharmaceutical Treating Chronic Myeloid Leukemia by Phase Revenue, Gross Margin and Market Share (2019-2024)
        7.16.5 Qilu Pharmaceutical Recent Developments/Updates
        7.16.6 Qilu Pharmaceutical Competitive Strengths & Weaknesses
    7.17 CSPC Ouyi Pharmaceutical
        7.17.1 CSPC Ouyi Pharmaceutical Details
        7.17.2 CSPC Ouyi Pharmaceutical Major Business
        7.17.3 CSPC Ouyi Pharmaceutical Treating Chronic Myeloid Leukemia by Phase Product and Services
        7.17.4 CSPC Ouyi Pharmaceutical Treating Chronic Myeloid Leukemia by Phase Revenue, Gross Margin and Market Share (2019-2024)
        7.17.5 CSPC Ouyi Pharmaceutical Recent Developments/Updates
        7.17.6 CSPC Ouyi Pharmaceutical Competitive Strengths & Weaknesses
    7.18 Suzhou Thery Pharmaceutical
        7.18.1 Suzhou Thery Pharmaceutical Details
        7.18.2 Suzhou Thery Pharmaceutical Major Business
        7.18.3 Suzhou Thery Pharmaceutical Treating Chronic Myeloid Leukemia by Phase Product and Services
        7.18.4 Suzhou Thery Pharmaceutical Treating Chronic Myeloid Leukemia by Phase Revenue, Gross Margin and Market Share (2019-2024)
        7.18.5 Suzhou Thery Pharmaceutical Recent Developments/Updates
        7.18.6 Suzhou Thery Pharmaceutical Competitive Strengths & Weaknesses
    7.19 Lunan Pharmaceutical
        7.19.1 Lunan Pharmaceutical Details
        7.19.2 Lunan Pharmaceutical Major Business
        7.19.3 Lunan Pharmaceutical Treating Chronic Myeloid Leukemia by Phase Product and Services
        7.19.4 Lunan Pharmaceutical Treating Chronic Myeloid Leukemia by Phase Revenue, Gross Margin and Market Share (2019-2024)
        7.19.5 Lunan Pharmaceutical Recent Developments/Updates
        7.19.6 Lunan Pharmaceutical Competitive Strengths & Weaknesses

8 Industry Chain Analysis
    8.1 Treating Chronic Myeloid Leukemia by Phase Industry Chain
    8.2 Treating Chronic Myeloid Leukemia by Phase Upstream Analysis
    8.3 Treating Chronic Myeloid Leukemia by Phase Midstream Analysis
    8.4 Treating Chronic Myeloid Leukemia by Phase Downstream Analysis

9 Research Findings and Conclusion

10 Appendix
    10.1 Methodology
    10.2 Research Process and Data Source
    10.3 Disclaimer

Table of Figures

List of Tables
 Table 1. World Treating Chronic Myeloid Leukemia by Phase Revenue by Region (2019, 2023 and 2030) & (USD Million), (by Headquarter Location)
 Table 2. World Treating Chronic Myeloid Leukemia by Phase Revenue by Region (2019-2024) & (USD Million), (by Headquarter Location)
 Table 3. World Treating Chronic Myeloid Leukemia by Phase Revenue by Region (2025-2030) & (USD Million), (by Headquarter Location)
 Table 4. World Treating Chronic Myeloid Leukemia by Phase Revenue Market Share by Region (2019-2024), (by Headquarter Location)
 Table 5. World Treating Chronic Myeloid Leukemia by Phase Revenue Market Share by Region (2025-2030), (by Headquarter Location)
 Table 6. Major Market Trends
 Table 7. World Treating Chronic Myeloid Leukemia by Phase Consumption Value Growth Rate Forecast by Region (2019 & 2023 & 2030) & (USD Million)
 Table 8. World Treating Chronic Myeloid Leukemia by Phase Consumption Value by Region (2019-2024) & (USD Million)
 Table 9. World Treating Chronic Myeloid Leukemia by Phase Consumption Value Forecast by Region (2025-2030) & (USD Million)
 Table 10. World Treating Chronic Myeloid Leukemia by Phase Revenue by Player (2019-2024) & (USD Million)
 Table 11. Revenue Market Share of Key Treating Chronic Myeloid Leukemia by Phase Players in 2023
 Table 12. World Treating Chronic Myeloid Leukemia by Phase Industry Rank of Major Player, Based on Revenue in 2023
 Table 13. Global Treating Chronic Myeloid Leukemia by Phase Company Evaluation Quadrant
 Table 14. Head Office of Key Treating Chronic Myeloid Leukemia by Phase Players
 Table 15. Treating Chronic Myeloid Leukemia by Phase Market: Company Product Type Footprint
 Table 16. Treating Chronic Myeloid Leukemia by Phase Market: Company Product Application Footprint
 Table 17. Treating Chronic Myeloid Leukemia by Phase Mergers & Acquisitions Activity
 Table 18. United States VS China Treating Chronic Myeloid Leukemia by Phase Revenue Comparison, (2019 & 2023 & 2030) & (USD Million)
 Table 19. United States VS China Treating Chronic Myeloid Leukemia by Phase Consumption Value Comparison, (2019 & 2023 & 2030) & (USD Million)
 Table 20. United States Based Treating Chronic Myeloid Leukemia by Phase Companies, Headquarters (States, Country)
 Table 21. United States Based Companies Treating Chronic Myeloid Leukemia by Phase Revenue, (2019-2024) & (USD Million)
 Table 22. United States Based Companies Treating Chronic Myeloid Leukemia by Phase Revenue Market Share (2019-2024)
 Table 23. China Based Treating Chronic Myeloid Leukemia by Phase Companies, Headquarters (Province, Country)
 Table 24. China Based Companies Treating Chronic Myeloid Leukemia by Phase Revenue, (2019-2024) & (USD Million)
 Table 25. China Based Companies Treating Chronic Myeloid Leukemia by Phase Revenue Market Share (2019-2024)
 Table 26. Rest of World Based Treating Chronic Myeloid Leukemia by Phase Companies, Headquarters (Province, Country)
 Table 27. Rest of World Based Companies Treating Chronic Myeloid Leukemia by Phase Revenue (2019-2024) & (USD Million)
 Table 28. Rest of World Based Companies Treating Chronic Myeloid Leukemia by Phase Revenue Market Share (2019-2024)
 Table 29. World Treating Chronic Myeloid Leukemia by Phase Market Size by Type, (USD Million), 2019 & 2023 & 2030
 Table 30. World Treating Chronic Myeloid Leukemia by Phase Market Size Value by Type (2019-2024) & (USD Million)
 Table 31. World Treating Chronic Myeloid Leukemia by Phase Market Size by Type (2025-2030) & (USD Million)
 Table 32. World Treating Chronic Myeloid Leukemia by Phase Market Size by Application, (USD Million), 2019 & 2023 & 2030
 Table 33. World Treating Chronic Myeloid Leukemia by Phase Market Size by Application (2019-2024) & (USD Million)
 Table 34. World Treating Chronic Myeloid Leukemia by Phase Market Size by Application (2025-2030) & (USD Million)
 Table 35. Novartis Basic Information, Manufacturing Base and Competitors
 Table 36. Novartis Major Business
 Table 37. Novartis Treating Chronic Myeloid Leukemia by Phase Product and Services
 Table 38. Novartis Treating Chronic Myeloid Leukemia by Phase Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
 Table 39. Novartis Recent Developments/Updates
 Table 40. Novartis Competitive Strengths & Weaknesses
 Table 41. Bristol Myers Squibb Basic Information, Manufacturing Base and Competitors
 Table 42. Bristol Myers Squibb Major Business
 Table 43. Bristol Myers Squibb Treating Chronic Myeloid Leukemia by Phase Product and Services
 Table 44. Bristol Myers Squibb Treating Chronic Myeloid Leukemia by Phase Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
 Table 45. Bristol Myers Squibb Recent Developments/Updates
 Table 46. Bristol Myers Squibb Competitive Strengths & Weaknesses
 Table 47. Pfizer Basic Information, Manufacturing Base and Competitors
 Table 48. Pfizer Major Business
 Table 49. Pfizer Treating Chronic Myeloid Leukemia by Phase Product and Services
 Table 50. Pfizer Treating Chronic Myeloid Leukemia by Phase Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
 Table 51. Pfizer Recent Developments/Updates
 Table 52. Pfizer Competitive Strengths & Weaknesses
 Table 53. Hansoh Pharmaceutical Basic Information, Manufacturing Base and Competitors
 Table 54. Hansoh Pharmaceutical Major Business
 Table 55. Hansoh Pharmaceutical Treating Chronic Myeloid Leukemia by Phase Product and Services
 Table 56. Hansoh Pharmaceutical Treating Chronic Myeloid Leukemia by Phase Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
 Table 57. Hansoh Pharmaceutical Recent Developments/Updates
 Table 58. Hansoh Pharmaceutical Competitive Strengths & Weaknesses
 Table 59. Takeda Pharmaceuticals Basic Information, Manufacturing Base and Competitors
 Table 60. Takeda Pharmaceuticals Major Business
 Table 61. Takeda Pharmaceuticals Treating Chronic Myeloid Leukemia by Phase Product and Services
 Table 62. Takeda Pharmaceuticals Treating Chronic Myeloid Leukemia by Phase Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
 Table 63. Takeda Pharmaceuticals Recent Developments/Updates
 Table 64. Takeda Pharmaceuticals Competitive Strengths & Weaknesses
 Table 65. Sun Pharmaceuticals Basic Information, Manufacturing Base and Competitors
 Table 66. Sun Pharmaceuticals Major Business
 Table 67. Sun Pharmaceuticals Treating Chronic Myeloid Leukemia by Phase Product and Services
 Table 68. Sun Pharmaceuticals Treating Chronic Myeloid Leukemia by Phase Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
 Table 69. Sun Pharmaceuticals Recent Developments/Updates
 Table 70. Sun Pharmaceuticals Competitive Strengths & Weaknesses
 Table 71. Mylan Basic Information, Manufacturing Base and Competitors
 Table 72. Mylan Major Business
 Table 73. Mylan Treating Chronic Myeloid Leukemia by Phase Product and Services
 Table 74. Mylan Treating Chronic Myeloid Leukemia by Phase Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
 Table 75. Mylan Recent Developments/Updates
 Table 76. Mylan Competitive Strengths & Weaknesses
 Table 77. Dr. Reddy's Laboratories Basic Information, Manufacturing Base and Competitors
 Table 78. Dr. Reddy's Laboratories Major Business
 Table 79. Dr. Reddy's Laboratories Treating Chronic Myeloid Leukemia by Phase Product and Services
 Table 80. Dr. Reddy's Laboratories Treating Chronic Myeloid Leukemia by Phase Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
 Table 81. Dr. Reddy's Laboratories Recent Developments/Updates
 Table 82. Dr. Reddy's Laboratories Competitive Strengths & Weaknesses
 Table 83. Teva Basic Information, Manufacturing Base and Competitors
 Table 84. Teva Major Business
 Table 85. Teva Treating Chronic Myeloid Leukemia by Phase Product and Services
 Table 86. Teva Treating Chronic Myeloid Leukemia by Phase Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
 Table 87. Teva Recent Developments/Updates
 Table 88. Teva Competitive Strengths & Weaknesses
 Table 89. Eugia Pharma Basic Information, Manufacturing Base and Competitors
 Table 90. Eugia Pharma Major Business
 Table 91. Eugia Pharma Treating Chronic Myeloid Leukemia by Phase Product and Services
 Table 92. Eugia Pharma Treating Chronic Myeloid Leukemia by Phase Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
 Table 93. Eugia Pharma Recent Developments/Updates
 Table 94. Eugia Pharma Competitive Strengths & Weaknesses
 Table 95. Hetero Basic Information, Manufacturing Base and Competitors
 Table 96. Hetero Major Business
 Table 97. Hetero Treating Chronic Myeloid Leukemia by Phase Product and Services
 Table 98. Hetero Treating Chronic Myeloid Leukemia by Phase Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
 Table 99. Hetero Recent Developments/Updates
 Table 100. Hetero Competitive Strengths & Weaknesses
 Table 101. Sawai Pharmaceutical Basic Information, Manufacturing Base and Competitors
 Table 102. Sawai Pharmaceutical Major Business
 Table 103. Sawai Pharmaceutical Treating Chronic Myeloid Leukemia by Phase Product and Services
 Table 104. Sawai Pharmaceutical Treating Chronic Myeloid Leukemia by Phase Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
 Table 105. Sawai Pharmaceutical Recent Developments/Updates
 Table 106. Sawai Pharmaceutical Competitive Strengths & Weaknesses
 Table 107. Lupin Basic Information, Manufacturing Base and Competitors
 Table 108. Lupin Major Business
 Table 109. Lupin Treating Chronic Myeloid Leukemia by Phase Product and Services
 Table 110. Lupin Treating Chronic Myeloid Leukemia by Phase Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
 Table 111. Lupin Recent Developments/Updates
 Table 112. Lupin Competitive Strengths & Weaknesses
 Table 113. Apotex Basic Information, Manufacturing Base and Competitors
 Table 114. Apotex Major Business
 Table 115. Apotex Treating Chronic Myeloid Leukemia by Phase Product and Services
 Table 116. Apotex Treating Chronic Myeloid Leukemia by Phase Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
 Table 117. Apotex Recent Developments/Updates
 Table 118. Apotex Competitive Strengths & Weaknesses
 Table 119. Chia Tai Tianqing Pharmaceutical Basic Information, Manufacturing Base and Competitors
 Table 120. Chia Tai Tianqing Pharmaceutical Major Business
 Table 121. Chia Tai Tianqing Pharmaceutical Treating Chronic Myeloid Leukemia by Phase Product and Services
 Table 122. Chia Tai Tianqing Pharmaceutical Treating Chronic Myeloid Leukemia by Phase Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
 Table 123. Chia Tai Tianqing Pharmaceutical Recent Developments/Updates
 Table 124. Chia Tai Tianqing Pharmaceutical Competitive Strengths & Weaknesses
 Table 125. Qilu Pharmaceutical Basic Information, Manufacturing Base and Competitors
 Table 126. Qilu Pharmaceutical Major Business
 Table 127. Qilu Pharmaceutical Treating Chronic Myeloid Leukemia by Phase Product and Services
 Table 128. Qilu Pharmaceutical Treating Chronic Myeloid Leukemia by Phase Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
 Table 129. Qilu Pharmaceutical Recent Developments/Updates
 Table 130. Qilu Pharmaceutical Competitive Strengths & Weaknesses
 Table 131. CSPC Ouyi Pharmaceutical Basic Information, Manufacturing Base and Competitors
 Table 132. CSPC Ouyi Pharmaceutical Major Business
 Table 133. CSPC Ouyi Pharmaceutical Treating Chronic Myeloid Leukemia by Phase Product and Services
 Table 134. CSPC Ouyi Pharmaceutical Treating Chronic Myeloid Leukemia by Phase Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
 Table 135. CSPC Ouyi Pharmaceutical Recent Developments/Updates
 Table 136. CSPC Ouyi Pharmaceutical Competitive Strengths & Weaknesses
 Table 137. Suzhou Thery Pharmaceutical Basic Information, Manufacturing Base and Competitors
 Table 138. Suzhou Thery Pharmaceutical Major Business
 Table 139. Suzhou Thery Pharmaceutical Treating Chronic Myeloid Leukemia by Phase Product and Services
 Table 140. Suzhou Thery Pharmaceutical Treating Chronic Myeloid Leukemia by Phase Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
 Table 141. Suzhou Thery Pharmaceutical Recent Developments/Updates
 Table 142. Suzhou Thery Pharmaceutical Competitive Strengths & Weaknesses
 Table 143. Lunan Pharmaceutical Basic Information, Manufacturing Base and Competitors
 Table 144. Lunan Pharmaceutical Major Business
 Table 145. Lunan Pharmaceutical Treating Chronic Myeloid Leukemia by Phase Product and Services
 Table 146. Lunan Pharmaceutical Treating Chronic Myeloid Leukemia by Phase Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
 Table 147. Lunan Pharmaceutical Recent Developments/Updates
 Table 148. Lunan Pharmaceutical Competitive Strengths & Weaknesses
 Table 149. Global Key Players of Treating Chronic Myeloid Leukemia by Phase Upstream (Raw Materials)
 Table 150. Global Treating Chronic Myeloid Leukemia by Phase Typical Customers


List of Figures
 Figure 1. Treating Chronic Myeloid Leukemia by Phase Picture
 Figure 2. World Treating Chronic Myeloid Leukemia by Phase Total Revenue: 2019 & 2023 & 2030, (USD Million)
 Figure 3. World Treating Chronic Myeloid Leukemia by Phase Total Revenue (2019-2030) & (USD Million)
 Figure 4. World Treating Chronic Myeloid Leukemia by Phase Revenue by Region (2019, 2023 and 2030) & (USD Million), (by Headquarter Location)
 Figure 5. World Treating Chronic Myeloid Leukemia by Phase Revenue Market Share by Region (2019-2030), (by Headquarter Location)
 Figure 6. United States Based Company Treating Chronic Myeloid Leukemia by Phase Revenue (2019-2030) & (USD Million)
 Figure 7. China Based Company Treating Chronic Myeloid Leukemia by Phase Revenue (2019-2030) & (USD Million)
 Figure 8. Europe Based Company Treating Chronic Myeloid Leukemia by Phase Revenue (2019-2030) & (USD Million)
 Figure 9. Japan Based Company Treating Chronic Myeloid Leukemia by Phase Revenue (2019-2030) & (USD Million)
 Figure 10. South Korea Based Company Treating Chronic Myeloid Leukemia by Phase Revenue (2019-2030) & (USD Million)
 Figure 11. ASEAN Based Company Treating Chronic Myeloid Leukemia by Phase Revenue (2019-2030) & (USD Million)
 Figure 12. India Based Company Treating Chronic Myeloid Leukemia by Phase Revenue (2019-2030) & (USD Million)
 Figure 13. Treating Chronic Myeloid Leukemia by Phase Market Drivers
 Figure 14. Factors Affecting Demand
 Figure 15. World Treating Chronic Myeloid Leukemia by Phase Consumption Value (2019-2030) & (USD Million)
 Figure 16. World Treating Chronic Myeloid Leukemia by Phase Consumption Value Market Share by Region (2019-2030)
 Figure 17. United States Treating Chronic Myeloid Leukemia by Phase Consumption Value (2019-2030) & (USD Million)
 Figure 18. China Treating Chronic Myeloid Leukemia by Phase Consumption Value (2019-2030) & (USD Million)
 Figure 19. Europe Treating Chronic Myeloid Leukemia by Phase Consumption Value (2019-2030) & (USD Million)
 Figure 20. Japan Treating Chronic Myeloid Leukemia by Phase Consumption Value (2019-2030) & (USD Million)
 Figure 21. South Korea Treating Chronic Myeloid Leukemia by Phase Consumption Value (2019-2030) & (USD Million)
 Figure 22. ASEAN Treating Chronic Myeloid Leukemia by Phase Consumption Value (2019-2030) & (USD Million)
 Figure 23. India Treating Chronic Myeloid Leukemia by Phase Consumption Value (2019-2030) & (USD Million)
 Figure 24. Producer Shipments of Treating Chronic Myeloid Leukemia by Phase by Player Revenue ($MM) and Market Share (%): 2023
 Figure 25. Global Four-firm Concentration Ratios (CR4) for Treating Chronic Myeloid Leukemia by Phase Markets in 2023
 Figure 26. Global Four-firm Concentration Ratios (CR8) for Treating Chronic Myeloid Leukemia by Phase Markets in 2023
 Figure 27. United States VS China: Treating Chronic Myeloid Leukemia by Phase Revenue Market Share Comparison (2019 & 2023 & 2030)
 Figure 28. United States VS China: Treating Chronic Myeloid Leukemia by Phase Consumption Value Market Share Comparison (2019 & 2023 & 2030)
 Figure 29. World Treating Chronic Myeloid Leukemia by Phase Market Size by Type, (USD Million), 2019 & 2023 & 2030
 Figure 30. World Treating Chronic Myeloid Leukemia by Phase Market Size Market Share by Type in 2023
 Figure 31. Chronic Phase
 Figure 32. Accelerated Phase
 Figure 33. Blast Phase
 Figure 34. World Treating Chronic Myeloid Leukemia by Phase Market Size Market Share by Type (2019-2030)
 Figure 35. World Treating Chronic Myeloid Leukemia by Phase Market Size by Application, (USD Million), 2019 & 2023 & 2030
 Figure 36. World Treating Chronic Myeloid Leukemia by Phase Market Size Market Share by Application in 2023
 Figure 37. Hospitals
 Figure 38. Clinics
 Figure 39. Others
 Figure 40. World Treating Chronic Myeloid Leukemia by Phase Market Size Market Share by Application (2019-2030)
 Figure 41. Treating Chronic Myeloid Leukemia by Phase Industrial Chain
 Figure 42. Methodology
 Figure 43. Research Process and Data Source

Companies Mentioned

Novartis
Bristol Myers Squibb
Pfizer
Hansoh Pharmaceutical
Takeda Pharmaceuticals
Sun Pharmaceuticals
Mylan
Dr. Reddy's Laboratories
Teva
Eugia Pharma
Hetero
Sawai Pharmaceutical
Lupin
Apotex
Chia Tai Tianqing Pharmaceutical
Qilu Pharmaceutical
CSPC Ouyi Pharmaceutical
Suzhou Thery Pharmaceutical
Lunan Pharmaceutical